Targets of vitamin D receptor signaling in the mammary gland

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Welsh, JoEllen ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Breast cancer; Mammary gland; Vitamin D receptor; Vitamin D binding protein

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 24; CYTOCHROME P450 27B1; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DOWN REGULATION; GENOTYPE; HUMAN; IN VITRO STUDY; MAMMARY GLAND; NONHUMAN; PROTEIN EXPRESSION; VITAMIN METABOLISM;

EID: 39749152186     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.07s204     Document Type: Conference Paper

References (47)

1. 1 Deeb KK, Trump DL, Johnson CS 2007 Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 7: 684–700.
2. 2 Ordonez‐Moran P, Larriba MJ, Pendas‐Franco N, Aguilera O, Gonzalez‐Sancho JM, Munoz A 2005 Vitamin D and cancer: An update of in vitro and in vivo data. Front Biosci 10: 2723–2749.
3. 3 Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A, 2006 Vitamin D and cancer. J Steroid Biochem Mol Biol 102: 156–162.
4. 4 Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S 2006 Identification and characterization of noncalcemic, tissue‐selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116: 892–904.
5. 5 Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC 1987 Immunocytochemical detection of 1,25‐dihydroxyvitamin D3 receptor in breast cancer. Cancer Res 47: 6793–6799.
6. 6 Simboli‐Campbell M, Narvaez CJ, Tenniswood M, Welsh J 1996 1,25‐Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF‐7 breast cancer cells. J Steroid Biochem Mol Biol 58: 367–376.
7. 7 Colston KW, Berger U, Coombes RC 1989 Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1: 188–191.
8. 8 Lowe L, Hansen CM, Senaratne S, Colston KW 2003 Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res 164: 99–110.
9. 9 VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J 1998 Apoptotic regression of MCF‐7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 139: 2102–2110.
10. 10 Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC 1992 EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44: 2273–2280.
11. 11 Lipkin M, Newmark HL 1999 Vitamin D, calcium and prevention of breast cancer:a review. J Am Coll Nutr 18: 392S–397S.
12. 12 Welsh J 2004 Vitamin D and breast cancer: Insights from animal models. Am J Clin Nutr 80 (6 Suppl): 1721S–1724S.
13. 13 Jacobson EA, James KA, Newmark HL, Carroll KK 1989 Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12‐dimethylbenz(a)anthracene in female Sprague‐Dawley rats. Cancer Res 49: 6300–6303.
14. 14 Mehta RG 2004 Stage‐specific inhibition of mammary carcinogenesis by 1alpha‐hydroxyvitamin D5. Eur J Cancer 40: 2331–2337.
15. 15 Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS 1999 Association between low levels of 1,25‐dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2: 283–291.
16. 16 Berube S, Diorio C, Verhoek‐Oftedahl W, Brisson J 2004 Vitamin D, calcium and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 13: 1466–1472.
17. 17 Saramaki A, Banwell CM, Campbell MJ, Carlberg C 2006 Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34: 543–554.
18. 18 Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD 2004 Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25‐dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 64: 2143–2147.
19. 19 Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142–153.
20. 20 Pendas‐Franco N, Gonzalez‐Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A 2007 Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75: 193–207.
21. 21 Wang Q Lee D Sysounthone V Chandraratna RAS Christakos S Korah R Wieder R 2001 1,25‐dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function‐ and cell‐specific additive effects. Breast Cancer Res Treat 67: 157–168.
22. 22 Welsh J 1994 Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72: 537–545.
23. 23 Vandewalle B, Wattez N, Lefebvre J 1995 Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: Possible implication of intracellular calcium. Cancer Lett 97: 99–106.
24. 24 Elstner E, Linker Israeli M, Umiel T, Le J, Grillier I, Said J, Shintaku IP, Krajewski S, Reed JC, Binderup L, Koeffler HP, 1996 Combination of a potent 20‐epi‐vitamin D3 analogue (KH 1060) with 9‐cis‐retinoic acid irreversibly inhibits clonal growth, decreases bcl‐2 expression, and induces apoptosis in HL‐60 leukemic cells. Cancer Res 56: 3570–3576.
25. 25 Benassi L, Ottani D, Fantini F, Marconi A, Chiodino C, Giannetti A, Pincelli C 1997 1,25‐dihydroxyvitamin D3, transforming growth factor beta1, calcium, and ultraviolet B radiation induce apoptosis in cultured human keratinocytes. J Invest Dermatol 109: 276–282.
26. 26 Guzey M, Kitada S, Reed JC 2002 Apoptosis induction by 1alpha,25‐dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1: 667–677.
27. 27 Narvaez CJ, Welsh J 2001 Role of mitochondria and caspases in vitamin D‐mediated apoptosis of MCF‐7 breast cancer cells. J Biol Chem 276: 9101–9107.
28. 28 Zinser GM, McEleney K, Welsh J 2003 Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol 200: 67–80.
29. 29 Valrance ME, Brunet AH, Welsh J 2007 VDR dependent inhibition of mammary tumor growth by EB1089 and UV radiation in vivo. Endocrinology 148: 4887–4894.
30. 30 Blutt SE, McDonnell TJ, Polek TC, Weigel NL 2000 Calcitriol‐induced apoptosis in LNCaP cells is blocked by overexpression of Bcl‐2. Endocrinology 141: 10–17.
31. 31 Rozenchan PB, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM 2004 Ras activation is associated with vitamin D receptor mRNA instability in HC11 mammary cells. J Steroid Biochem Mol Biol 92: 89–95.
32. 32 Agadir A, Lazzaro G, Zheng Y, Zhang XK, Mehta R 1999 Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 20: 577–582.
33. 33 Narvaez CJ, Vanweelden K, Byrne I, Welsh J 1996 Characterization of a vitamin D3‐resistant MCF‐7 cell line. Endocrinology 137: 400–409.
34. 34 Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L 2001 MCF‐7/VD(R): A new vitamin D resistant cell line. J Cell Biochem 82: 422–436.
35. 35 Byrne B, Welsh J 2007 Identification of novel mediators of vitamin D signaling and 1,25(OH)(2)D(3) resistance in mammary cells. J Steroid Biochem Mol Biol 103: 703–707.
36. 36 Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D 2000 Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25: 144–146.
37. 37 Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M 2005 Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11: 3579–3586.
38. 38 Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ 2006 Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 12: 2004–2013.
39. 39 Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC 1988 Immunocytochemical detection of 1,25‐dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67: 607–613.
40. 40 Kemmis CM, Salvador SM, Smith KM, Welsh J 2006 Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25‐hydroxyvitamin D‐3, the major circulating form of vitamin D‐3. J Nutr 136: 887–892.
41. 41 Zinser G, Packman K, Welsh J 2002 Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129: 3067–3076.
42. 42 Zinser GM, Welsh J 2004 Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 18: 2208–2223.
43. 43 Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ 2003 Vitamin D‐3 receptor as a target for breast cancer prevention. J Nutr 133 (7 Suppl): 2425S–2433S.
44. 44 Rowling MJ, Kemmis CM, Taffany DA, Welsh J 2006 Megalin‐mediated endocytosis of vitamin D binding protein correlates with 25‐hydroxycholecalciferol actions in human mammary cells. J Nutr 136: 2754–2759.
45. 45 Zinser GM, Welsh J 2004 Effect of Vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. J Steroid Biochem Mol Biol 89–90: 433–436.
46. 46 Zinser GM, Welsh J 2004 Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV‐neu mice. Carcinogenesis 25: 2361–2372.
47. 47 Zinser GM, Sundberg JP, Welsh J 2002 Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 23: 2103–2109.